News

What is new at EpiPharm

2019

March 25, 2019

RESI Conference, Vienna, Austria
Meet us at the RESI

Redefining Early Stage Investments Conference in Vienna, Austria EpiPharm will be represented by Dr. Rosemarie Sift Carter, CEO and Dr. Robert Carter Head of Development and Regulatory.
Please send your meeting requests via the partnering system or by mailto 
robert.carter@epipharm.ch

RESI Innovation Challenge, Vienna, Austria

EpiPharm’s project was selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge as one of the most innovative applicants. It will be presented at the RESI Innovation Challenge showcase.

March 25 - 27, 2019

     Meet us at the Bio-Europe Spring Conference, Vienna, Austria
     EpiPharm will be represented by Mark Palmer, Managing Director, Triad Healthcare Partners
     Please send your meeting requests for partnering to:
     mpalmer@triadsecurities.com

January 7 - 10, 2019

Meet us at the 37th Annual J.P. Morgan Healthcare Conference, San Francisco, California
EpiPharm will be represented by Mark Palmer, Mark M. Palmer, Managing Director, Triad Healthcare Partners
Please send your meeting requests for partnering to:
mpalmer@triadsecurities.com

2018  

November, 2018:

EpiPharm AG is proud to announce the online publication in the British Journal of
Dermatology of the exploratory study on the topical use of artemether in patients with
seborrheic keratosis. Data demonstrate clinically relevant improvement with long lasting
effect in 2/3 of lesions treated. (BJD 2018; 179, pp 1225-1225)

August, 2018:

EpiPharm AG announces the issuance of the European patent for use of artemisinins for the treatment of seborrheic keratosis.

June, 2018:

EpiPharm is pleased to announce the selection of a faster acting and more potent member of the artemisinin class as lead compound and progression to phase 2.

April, 2018:

EpiPharm AG announces the issuance of the US patent for use of artemisinins for the treatment of seborrheic keratosis.